Research AppraisalSystematic Review

The calcium-sensing receptor in sepsis and septic shock, mechanistic pathways and translational perspectives: a systematic review.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]Janssen, Valentine, Kamel, Saïd, Slama, Michel et al.17 Apr 2026DOI

Clinical Snapshot

70CEBM
Evidence: ModerateSystematic Review

PICO Framework

P — PopulationAdult mammalian models and humans with sepsis or septic shock
I — InterventionCalcium-sensing receptor (CaSR) expression, activation, or antagonism
C — ComparatorControl conditions or baseline CaSR activity
O — OutcomesInflammatory response, cytokine release, organ injury, mortality in sepsis models

Bottom Line

This systematic review identifies the calcium-sensing receptor as a potential amplifier of inflammatory responses in sepsis, with consistent upregulation in immune cells and promotion of IL-1β release via the NLRP3 inflammasome. While preclinical models suggest CaSR antagonists may mitigate inflammation and organ injury, the evidence base consists entirely of in vitro and animal studies. No randomized controlled trials were identified, and clinical data remain sparse. The mechanistic insights are valuable for understanding sepsis pathophysiology, but translation to clinical practice requires substantial additional research including human studies validating CaSR expression patterns in septic patients and clinical trials testing CaSR antagonists. Australian intensivists should view this as promising basic science that may inform future therapeutic development rather than immediately actionable clinical evidence.

Evidence: Moderate

Key Findings

  • P Value: Not applicable - narrative synthesis

  • Effect Size: Not quantified - qualitative synthesis only

  • Primary Outcome: CaSR consistently upregulated in immune cells following bacterial/inflammatory stimuli

  • Nnt Or Sensitivity: CaSR activation promotes IL-1β release via NLRP3 inflammasome pathway

  • Confidence Interval: Not applicable - no meta-analysis performed

Clinical Application

CaSR antagonists show promise in preclinical models but require clinical trials before implementation Relevant to Australian ICUs managing sepsis, but TGA approval would require robust clinical trial data currently lacking Critically ill patients with sepsis or septic shock, though clinical validation required

Abstract

BACKGROUND: Sepsis and septic shock are major causes of mortality in critically ill patients. They are linked to widespread metabolic and immune dysregulation, including alterations in calcium and phosphate homeostasis. The calcium-sensing receptor (CaSR) not only plays a role in mineral balance, but also modulates key immune pathways and may contribute to the pathogenesis of sepsis. METHODS: A systematic literature review was conducted according to PRISMA 2020 guidelines. Four databases (PubMed, EMBASE, Cochrane Library, and Google Scholar) were searched for studies published since 1990. To be eligible for inclusion, articles had to be original research, reviews, or clinical trials involving adult models (mammalian or human). Full-text availability was required. Risk of bias was assessed for all studies included. RESULTS: Sixty-six articles met the inclusion criteria: 49 original studies and 17 reviews. No randomized controlled trials or meta-analyses were identified. Most studies relied on in vitro or in vivo models. CaSR was consistently reported to be upregulated or activated following exposure to bacterial and inflammatory stimuli in immune cells, including monocytes and lymphocytes. CaSR activation promotes proinflammatory cytokine release, notably IL-1β via the NOD like receptor family 3 (NLRP3) inflammasome although results in intestinal epithelial models remain inconsistent. In non-septic models, CaSR activation was associated with tissue and organ injury, including renal and cardiac damage, as well as vasoplegia related to endothelial dysfunction. Preclinical models of pneumonia and endotoxemia suggest that CaSR antagonists may effectively mitigate inflammation and organ injury. CONCLUSION: This systematic review identifies the CaSR as an amplifier of the host inflammatory response across both septic and non-septic preclinical models The lack of robust clinical data underscores the need for translational studies assessing CaSR expression or activity in patients with sepsis or septic shock, alongside in vivo validation of CaSR inhibition as a therapeutic strategy.

References

  1. 1.Janssen, V., Kamel, S., Slama, M., Abou-Arab, O., Brazier, M., Mentaverri, R., & Mary, A. (2026). The calcium-sensing receptor in sepsis and septic shock, mechanistic pathways and translational perspectives: a systematic review. Inflammation Research. https://doi.org/10.1002/biof.70009
Share:XLinkedIn

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service